Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Apr 25, 2024 (2 years ago)

MethylPREDNISolone Acetate Injectable Suspension

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of Particulate Matter: Potential for black particulates in the drug product.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

MethylPREDNISolone Acetate Injectable Suspension, USP, 400 mg per 10 mL (40 mg per mL), 1 x 10 mL Multi-Dose Vial, Rx only, Mfd. for SAGENT Pharmaceuticals, Schaumburg, IL 60195, Made in India. NDC: 25021-820-10

Affected NDC 25021-0820-10

Compare with the code on your package — it is the most precise check available.

Drug: Methylprednisolone

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
methylprednisolone acetate
NDC 25021-0820
40 mg/mL Injection, Suspension
Intra-Articular|intralesional|intramuscular|intrasynovial|soft Tissue
Sagent Pharmaceuticals Rx
Recalling firm
Sagent Pharmaceuticals
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0499-2024 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Methylprednisolone recalls

See all
Class II · Moderate risk

methylprednisolone tablets

Labeling: Not Elsewhere Classified. Incorrect orientation of the blister foil applied to the blister cavities, which results in incorrect dosing information when following the directions on the foil.

Ongoing Labeling / mix-up Greenstone Llc NDC 59762-4440-2 D-0299-2026
Class III · Low risk

Methylprednisolone Acetate Injectable Suspension

Labeling: Not Elsewhere Classified; A typographical error was observed in the NDC number on the preprinted Individual Folding Cartons (secondary packaging only). Incorrect NDC Number 70121-1573-1; Correct NDC Number 70121-1574-1.

Terminated Labeling / mix-up Amneal Pharmaceuticals of New York, LLC NDC 70121-1574-01 D-0756-2023
Class II · Moderate risk

Depo-Medrol

cGMP deviations: Temperature abuse

Terminated Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 0009-3475-01 D-1097-2022

Other recalls by Sagent Pharmaceuticals

All 2024 recalls
Class I · High risk

Docetaxel Injection

Presence of Particulate Matter: Presence of particulate matter from the stopper in the drug product.

Ongoing Particulate / foreign matter Sagent Pharmaceuticals NDC 25021-254-08 D-0554-2024
Class I · High risk

Docetaxel Injection

Presence of Particulate Matter: Presence of particulate matter from the stopper in the drug product.

Ongoing Particulate / foreign matter Sagent Pharmaceuticals NDC 25021-254-08 D-0553-2024